Dr. Reddy's Laboratories Ltd. News and Updates

Keep track of all breaking news on Dr. Reddy's Laboratories Ltd. from all sources in a single place.

Load latest

Dr. Reddy's Laboratories Ltd.

09 Apr 2025, 11:00PM

1268.60

-0.06%

US tariffs on Pharma: Dr Reddy's to Sun Pharmacan Indian drugmakers escape Trump's tariff tantrums?

livemint

US tariffs on Pharma: India currently levies up to 10% import duties on drugs imported from the US with several drugs having lower duty of 5% while around 150 drugs are exempted from duties.

Dr. Reddy's Laboratories Ltd.'s price crossed below 50Day SMA today

Dr. Reddy's Laboratories Ltd.

09 Apr 2025, 04:59PM

1268.60

-0.06%

Kyndryl partners with Dr Reddy's to automate IT ops with AI-powered platform

Business Line

The initiative will implement a Zero Touch IT Operations model using Kyndryl's Dual Model IT Ops framework, targeting a 60% reduction in manual interventions

Geojit BNP Paribas released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1150.0 on 07 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

07 Apr 2025

1268.60

-0.06%

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

Business Standard

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

05 Apr 2025

1268.60

-0.06%

Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority

Business Standard

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

Dr. Reddy's Laborato.. has an average target of 1321.50 from 8 brokers.

Dr. Reddy's faces 2,395 crore tax reassessment notice

Business Line | 05 Apr 2025

Dr. Reddy's Laboratories Ltd.

26 Mar 2025

1268.60

-0.06%

Bio-Thera, Dr. Reddy's partner for biosimilar expansion in Southeast Asia

Business Standard

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases

Dr. Reddy's Laboratories Ltd.'s price crossed below 50Day SMA today

Dr Reddy's inks exclusive commercialisation pact on biosimilars for Southeast Asia

Business Line | 26 Mar 2025

Dr. Reddy's Laboratories Ltd.

13 Mar 2025

1268.60

-0.06%

Dr Reddy's Recalls Epilepsy Drug Levetiracetam In US Over Mislabelling Concerns

NDTV Profit

The pharmaceutical company issued a risk statement that the patients who are administered the mislabelled product will likely experience serious side effects.

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1304.9

Dr. Reddy's recalls Levetiracetam Sodium Chloride Injection in US market

Business Line | 13 Mar 2025

Dr. Reddy's Laboratories Ltd.

25 Feb 2025

1268.60

-0.06%

Dr Reddy's Laboratories' Facility Gets FDA EIR With Voluntary-Action-Indicated Classification

NDTV Profit

The VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Indian drugmakers to stay competitive despite US tariff plans: Dr Reddy's

Business Standard | 25 Feb 2025

Dr. Reddy's Laboratories Ltd.

06 Feb 2025

1268.60

-0.06%

Dr Reddy's Unit Ties Up With Shanghai Henlius Biotech

NDTV Profit

As part of the tie-up, Henlius will be responsible for development, manufacturing and commercial supply, and may receive up to a total of $131.6 million.

Geojit BNP Paribas released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1150.0 on 07 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

25 Jan 2025

1268.60

-0.06%

Dr Reddys Laboratories Q3 Results 2025 on 25 Jan, 2025: profit rise by 2.38% YOY, profit at 1413.7 crore and revenue at 8381.2 crore

livemint

Dr Reddys Laboratories Q3 Results 2025 on 25 Jan, 2025: Revenue increased by 15.81% YoY & profit increased by 2.38% YoY, profit at 1413.7 crore and revenue at 8381.2 crore.